Universität zu Köln

Hallek, Michael and Pflug, Natali (2010). Chronic lymphocytic leukemia. Ann. Oncol., 21. S. 154 - 165. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041

Full text not available from this repository.

Abstract

The management of chronic lymphocytic leukemia (CLL) is currently undergoing a profound change. First, several new drugs have been approved (fludarabine, bendamustine and two monoclonal antibodies, alemtuzumab and rituximab). In addition, novel monoclonal antibodies targeting CD20, CD23, CD37 or CD40, as well as drugs designed to interfere with central pathways regulating the cell cycle, the apoptotic machinery, or the leukemic microenvironment (flavopiridol, oblimersen, ABT-263 or lenalidomide) are being tested in clinical trials. Furthermore, improved protocols using reduced-intensity allogeneic progenitor cell transplantation makes it possible to offer this procedure to more patients with CLL. Finally, new prognostic markers that may influence therapeutic decisions have been identified. This review attempts to summarize the current knowledge in this rapidly moving field.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Hallek, Michael UNSPECIFIED UNSPECIFIED UNSPECIFIED Pflug, Natali UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-494565
DOI:	10.1093/annonc/mdq373
Journal or Publication Title:	Ann. Oncol.
Volume:	21
Page Range:	S. 154 - 165
Date:	2010
Publisher:	OXFORD UNIV PRESS
Place of Publication:	OXFORD
ISSN:	1569-8041
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language FLUDARABINE PLUS CYCLOPHOSPHAMIDE; PHASE-III TRIAL; PREVIOUSLY UNTREATED PATIENTS; PROGRESSION-FREE SURVIVAL; RESIDUAL DISEASE; 1ST-LINE THERAPY; RITUXIMAB THERAPY; CLINICAL-EFFICACY; INITIAL THERAPY; 1ST REMISSION Multiple languages Oncology Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/49456